Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Plastomics Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are located in 2 distinct art units, indicating that each case falls into a different technical category. There are 2 distinct examiners assigned, so each pending action is being reviewed by a different person. This means that the company must address two different individual review styles across two different art units. The 2 pending office actions represent the current scope of the company's patent prosecution in this sector.
DELEO, VICTORIA LYNN is the busiest examiner, managing 1 pending office action. The other action is handled by the other distinct examiner. Since each of the 2 distinct examiners has 1 action, the workload is evenly split. Practitioners should note that the 2 pending office actions are subject to the interpretations of 2 different people in 2 different art units. This requires a strategy that accounts for the specific requirements of each art unit while responding to 2 unique examiners. The 2 pending office actions are the focus of the company's current efforts.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DELEO, VICTORIA LYNN | 1 | 41.4% | -44.4% |
| SPEED, DEQUANTARIUS JAVON | 1 | 70.0% | +69.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19311616 | PLASTID TRANSFORMATION BY COMPLEMENTATION OF PLASTID MUTATIONS | DELEO, VICTORIA LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18142777 | Plastid-transgene-encoded nuclear gene silencing | SPEED, DEQUANTARIUS JAVON | 12d |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19311616 | PLASTID TRANSFORMATION BY COMPLEMENTATION OF PLASTID MUTATIONS | DELEO, VICTORIA LYNN | 1662 | §101§102§103§112DP | Non-Final OA | — | Pending | Aug 27, 2025 |
| 18142777 | Plastid-transgene-encoded nuclear gene silencing | SPEED, DEQUANTARIUS JAVON | 1663 | §112 | Non-Final OA | 12d | Pending | May 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial